HDFC Life Insurance vs Niva Bupa Health Q4 FY26

HDFC Life reported FY26 PAT of ₹1,910 crore and VNB of ₹4,340 crore (+2% YoY), with new business margins at 24.2% (down 140bps YoY) due to GST/surrender value impact (130bps), fixed cost absorption (90bps), and assumption strengthening (40bps), partly offset by better product mix (120bps). Individual APE grew 7% YoY, with retail protection surging 43% and agency channel outpacing the company by 500bps. However, Q4 saw a sharp slowdown driven by unabsorbed GST, temporary softness in bancassurance, and deferment of demand amid global uncertainty. Management expects GST headwinds to neutralize by H1 FY27 and aims to outpace industry growth, but near-term visibility is low. Key risk: competitive intensity in the HDFC Bank channel may persist, pressuring counter share and growth.

Guidance read

GST impact to be neutralized by H1 FY27: Management expects the GST headwind on margins to taper off and be largely neutralized as the company moves into FY27. VNB growth to be in line with APE growth in FY27: Priority is to restore growth and deliver VNB growth at least in line with APE growth, with margin expansion secondary. Target to outpace industry new business and VNB growth: Aspiration to grow faster than the industry in new business and VNB remains unchanged, though near-term guidance is not quantified. Capital raise of ₹1,000 crore via preferential issue to HDFC Bank: Board approved raising up to ₹1,000 crore through preferential issue to parent HDFC Bank, adding ~900bps to solvency.

Risk read

Key risks include Competitive intensity in HDFC Bank channel — Counter share in HDFC Bank declined to early 60s in FY26 from mid-60s, driven by aggressive pricing by competitors, especially in non-par savings.; Regulatory changes (commission caps, IFRS, RBC) — Potential commission caps and transition to IFRS/RBC could disrupt business models; management seeks forbearance for IFRS until FY28.; Persistency deterioration — 13-month persistency dropped 200bps, though management says trends stabilized in Q4; further deterioration could impact margins and EV.; CEO tenure uncertainty — MD & CEO Vibha Padalkar's current term ends in September 2026; regulatory interpretation of 15-year limit may affect continuity..

Promise ledger

Scorecard data is being built as historical quarters are processed.

Niva Bupa delivered a strong Q4 FY26 with GWP growth of 27.4% to ₹9,433 crore, driven by retail health growth of 35% and market share expansion to 10.4% in Q4. PAT surged 80% to ₹366 crore, with combined ratio improving 160 bps to 101.4% on operating leverage. Management guided for sustained retail industry growth of 17-19% CAGR and expects combined ratio to reach ~99% by FY29, with expense ratio savings offsetting modest loss ratio uptick. Key risks include potential commission cap regulation and competitive pressure from GST-driven volume growth normalization.

Guidance read

Combined ratio target of ~99% by FY29: Management expects combined ratio to improve to ~99% by FY29, driven by expense ratio savings of 200-250 bps. Retail health industry growth of 17-19% CAGR over 5 years: Management reiterated view that retail health industry will grow at 17-19% CAGR over a 5-year horizon. Loss ratio may inch up by ~150 bps: Management guided that loss ratio may increase by about 150 bps over time, offset by expense ratio improvements.

Risk read

Key risks include Potential commission cap regulation — Regulatory changes could cap commission rates, impacting distribution costs and growth. Management awaits clarity but believes single expense limit is preferable.; Normalization of GST-driven growth — Industry growth may moderate as the GST tailwind fades. Management expects stabilization at 17-19% CAGR, but near-term volatility is possible.; Group health loss ratio volatility — Group health loss ratio was ~60.5% for FY26, and IFRS loss components on onerous contracts could signal underwriting risk..

Promise ledger

Scorecard data is being built as historical quarters are processed.